Glenmark Pharmaceuticals announced that its Monroe, North Carolina manufacturing plant received a Form 483 with five observations from the USFDA following a GMP inspection conducted in June 2025. The company stated that the observations are procedural and don't involve data integrity issues. Glenmark is committed to addressing the concerns and will respond to the USFDA within the required timeframe.